Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | REN | P00797 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5349089 | 0.90 | PSMB1 (0.51) | CTSKCACNA1BPSMB1PSMB8PSMB9 | |
| SCHEMBL5351816 | 0.89 | GRN (0.43) | CTSKCACNA1BCTSSRENPSMB1 | |
| SCHEMBL5124536 | 0.88 | CTSK (0.47) | CTSKCACNA1BCTSSRENALDH1A1 | |
| SCHEMBL5124003 | 0.87 | CTSK (0.45) | CTSKCACNA1BCTSSRENACE | |
| SCHEMBL5123388 | 0.84 | CTSK (0.47) | CTSKCTSSRENHTT | |
| SCHEMBL4841915 | 0.82 | CACNA1B (0.59) | CACNA1BALDH1A1LMNAHRH3 | |
| SCHEMBL5350415 | 0.81 | HTT (0.52) | CACNA1BMMP13ALDH1A1LMNAHRH3 | |
| SCHEMBL5355876 | 0.81 | CACNA1B (0.51) | CACNA1BALDH1A1LMNAHRH3 | |
| SCHEMBL5355126 | 0.81 | MAPK14 (0.42) | CTSKCACNA1BCTSSRENALDH1A1 | |
| SCHEMBL4846817 | 0.81 | CACNA1B (0.59) | CTSKCACNA1BMMP13CTSSREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0997147-B1 | AMINO ACID DERIVATIVES | ONO PHARMACEUTICAL CO (JP) | 2006-03-15 | — | — | EP | claimed |
| US-20030013725-A1 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-01-16 | — | — | US | claimed |
| EP-0997147-A1 | AMINO ACID DERIVATIVES | Ono Pharmaceutical Co., Ltd. (JP) | 2000-05-03 | — | — | EP | claimed |
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | disclosed |
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| EP-0997147-B1 | AMINO ACID DERIVATIVES | ONO PHARMACEUTICAL CO (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6903119-B1 | Amino acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-20030013725-A1 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-01-16 | — | — | US | disclosed |
| EP-1097929-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-09 | — | — | EP | disclosed |
| EP-0997147-A1 | AMINO ACID DERIVATIVES | Ono Pharmaceutical Co., Ltd. (JP) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1B, CACNA1A | CTSK 895/4885CACNA1B 2/4885MMP13 2245/4885 |
| US-20030013725-A1 | Amino acid derivatives | CACNA1B, SCN1A, SCN2A | CTSK 3691/4885CACNA1B 1/4885MMP13 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.